Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: Results from the phase 3 ASCLEPIOS I and II trials
Frontiers in Immunology
Open Access Publication
Rights and Permissions
Ziemssen T, Arnold DL, Alvarez E, Cross AH, Willi R, Li B, Kukkaro P, Kropshofer H, Ramanathan K, Merschhemke M, Kieseier B, Su W, Häring DA, Hauser SL, Kappos L and Kuhle J (2022) Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Front. Immunol. 13:852563. doi: 10.3389/fimmu.2022.852563 © 2022 Ziemssen, Arnold, Alvarez, Cross, Willi, Li, Kukkaro, Kropshofer, Ramanathan, Merschhemke, Kieseier, Su, Häring, Hauser, Kappos and Kuhle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Ziemssen, Tjalf; Cross, Anne H; and et al., "Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: Results from the phase 3 ASCLEPIOS I and II trials." Frontiers in Immunology. 13, 852563 (2022).